Enicepatide

Enicepatide is a dual gastric inhibitory polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist. Enicepatide can be studied in antidiabetic research[1].

2869147-44-2

12352209

GCGR; Insulin Receptor

GPCR/G Protein; Protein Tyrosine Kinase/RTK

Metabolic Disease

O=C(N[C@@H](CCC(O)=O)C(NCC(N[C@@H]([C@H](O)C)C(N[C@@H](CC1=CC=CC=C1)C(N[C@@H]([C@H](O)C)C(N[C@@H](CO)C(N[C@@H](CC(O)=O)C(N[C@@H](CC2=CC=C(C=C2)O)C(N[C@@H](CO)C(N[C@@H]([C@@H](C)CC)C(NC(C)(C)C(N[C@@H](CC(C)C)C(N[C@@H](CC(O)=O)C(N[C@@H](CCCCN)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](C)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCCCNC(COCCOCCNC(COCCOCCNC(CC[C@H](NC(CCCCCCCCCCCCCCCCCCC(O)=O)=O)C(O)=O)=O)=O)=O)C(N[C@@H](C)C(N[C@@H](CC3=CC=CC=C3)C(N[C@@H](C(C)C)C(N[C@@H](CCC(N)=O)C(N[C@@H](CC4=CNC5=CC=CC=C45)C(N[C@@H](CC(C)C)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](C)C(NCC(NCC(N6[C@@H](CCC6)C(N[C@@H](CO)C(N[C@@H](CO)C(NCC(N[C@@H](C)C(N7[C@@H](CCC7)C(N8[C@@H](CCC8)C(N9[C@@H](CCC9)C(N[C@@H](CO)C(N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CCNC(C(C)(C%10=CC(F)=CC(C#N)=C%10)C)=O

C226H345FN48O67

4825.44

[1]WHO Drug Information, Vol. 39, No. 2, 2025

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-P11237/

Peptides

No Development Reported